As of May 3, 2018 Veracyte Inc (NASDAQ:VCYT) Sellers Declined Their Shorts By 7.21%

May 3, 2018 - By Matthew Medley

Veracyte, Inc. (NASDAQ:VCYT) Corporate Logo

During Q4 2017 the big money sentiment decreased to 1.23. That’s change of 0.53, from 2017Q3’s 1.76. 15 investors sold all, 16 reduced holdings as Veracyte, Inc. ratio dived. 26 increased holdings while 12 funds amassed holdings. Funds hold 21.45 million shares thus 4.52% less from 2017Q3’s 22.46 million shares.
State Of Wisconsin Invest Board invested 0% of its capital in Veracyte, Inc. (NASDAQ:VCYT). Venbio Select Advisor Limited has invested 0.32% in Veracyte, Inc. (NASDAQ:VCYT). Grp One Trading Limited Partnership stated it has 50,129 shs. Spark Invest Mngmt Ltd Liability stated it has 34,500 shs. Blackrock reported 1.84 million shs. Acuta Llc owns 4.06% invested in Veracyte, Inc. (NASDAQ:VCYT) for 3.30M shs. Citigroup Inc accumulated 3,461 shs or 0% of the stock. Jpmorgan Chase And has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Grandeur Peak Global Advsr Limited Liability Company has invested 0.28% in Veracyte, Inc. (NASDAQ:VCYT). Deutsche Bankshares Ag has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Millennium Mgmt Limited Company owns 780,770 shs or 0.01% of their US capital. California State Teachers Retirement Systems owns 37,021 shs or 0% of their US capital. Tpg Grp Inc (Sbs) stated it has 3.55 million shs or 0.36% of all its holdings. Moreover, Renaissance Technology Limited Liability has 0% invested in Veracyte, Inc. (NASDAQ:VCYT) for 549,300 shs. 13,370 are held by Art Advisors.

Veracyte Inc (NASDAQ:VCYT) had a decrease of its shares shorted by 7.21%. FINRA announced shares shorted of VCYT’s total 857,300 shares. That’s 7.21% down from 923,900 shares. 11 days will cost VCYT with 74,900 average volume to restore its former position. Float short on Veracyte Inc is 4.11%.

VCYT is touching $5.67 during the last trading session, after decreased 4.38%.Veracyte, Inc. has volume of 54,242 shares. Since May 3, 2017 VCYT has declined 39.30% and is downtrending. The stock underperformed the S&P 500 by 50.85%.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States.The firm is valued at $194.74 million. The firm uses genomic technology to resolve diagnostic ambiguity.Last it reported negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

Veracyte, Inc. (NASDAQ:VCYT) Ratings Coverage

Total analysts of 3 have positions in Veracyte (NASDAQ:VCYT) as follows: 1 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 33%. Since November 7, 2017 according to StockzIntelligence Inc Veracyte has 4 analyst reports. In Wednesday, April 18 report Piper Jaffray maintained it with “Hold” rating and $4.9000 target. On Tuesday, November 7 Piper Jaffray downgraded the shares of VCYT in report to “Hold” rating. On Tuesday, November 7 Leerink Swann maintained the shares of VCYT in report with “Outperform” rating. On Tuesday, November 7 the firm earned “Neutral” rating by Janney Capital.

Veracyte, Inc. (NASDAQ:VCYT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: